Bayer Selects InforSense for Next Generation Integrative Analytics Infrastructure
News Sep 16, 2005
InforSense Ltd has announced that Bayer Healthcare AG, a member of the Bayer Group has selected InforSense technology to enhance their drug discovery informatics infrastructure.
InforSense's workflow-based integrative analytics environment, InforSense KDE, will provide Bayer with a flexible rapid application development platform to optimize their drug discovery decision-making.
"To identify and optimize potential drug leads, Bayer's chemists need both rapid processing of large compound libraries via chemical cartridge technology coupled with easy access to best of breed proprietary and third party analytic tools and visualizations," said Dr. Alexander Hillisch, Head of Computational Chemistry at Bayer Healthcare AG.
"InforSense Open Discovery Workflow™ technology offers the appropriate environment for rapidly composing data and applications, including our in-house in silico ADMET tools, to optimize our high-throughput cheminformatics analysis."
"We are delighted that Bayer has chosen InforSense," commented Joseph F. Donahue, Chief Business Officer, InforSense.
"InforSense KDE will facilitate the composition, integration and deployment of a wide range of cheminformatics applications by giving Bayer's computational chemists access to their chosen set of tools via cutting-edge workflow technology."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE